Cost-effectiveness of insulin detemir versus NPH for type I diabetes patients in a German setting. A modeling evaluation based upon results from a meta-analysis

被引：0
|
作者：
Kotchie, R. [1 ]
Scheijbeler, H. [1 ]
Aagren, M. [2 ]
Nielsen, S. [2 ]
Valentine, W. J. [3 ]
Goodall, G. [3 ]
机构：
[1] IMS Hlth, London, England
[2] Novo Nordisk AS, Virum, Denmark
[3] IMS Hlth, Basel, Switzerland
来源：
VALUE IN HEALTH | 2007年 / 10卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)64858-9
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A222 / A222
页数：1
相关论文
共 50 条
  • [21] EVALUATING THE COST-EFFECTIVENESS OF SWITCHING FROM INSULIN GLARGINE TO INSULIN DETEMIR IN PATIENTS WITH TYPE-2 DIABETES IN A CHINESE SETTING: A MODELING STUDY BASED ON THE PREDICTIVE STUDY
    Yang, L.
    Lay, A. L.
    Chang, J. H.
    [J]. VALUE IN HEALTH, 2011, 14 (03) : A97 - A97
  • [22] Long-term clinical outcomes of insulin detemir versus NPH based basal-bolus therapy for type I diabetes patients in Germany: A modeling analysis using results from a meta-analysis of three clinical trials
    Kotchie, R. W.
    Aagren, M.
    Valentine, W. J.
    Goodall, G.
    [J]. DIABETOLOGIA, 2007, 50 : S431 - S432
  • [23] Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 diabetes mellitus (T1DM) in the Canadian payer setting: Modeling analysis using a randomized controlled trial
    Minshall, M. E.
    Tunis, S. L.
    Conner, C.
    McCormick, J., I
    Kapor, J.
    Groleau, D.
    [J]. VALUE IN HEALTH, 2008, 11 (03) : A223 - A224
  • [24] Effectiveness and safety of insulin glargine versus detemir analysis in patients with type 1 diabetes: systematic review and meta-analysis
    Silva, Thales B. C.
    Almeida, Paulo H. R. F.
    Araujo, Vania E.
    Acurcio, Francisco de Assis
    Guerra Junior, Augusto A.
    Godman, Brian
    Alvares, Juliana
    [J]. THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2018, 9 (08) : 241 - 254
  • [25] Cost-effectiveness analysis of basal-bolus therapy of type 1 diabetes using insulin detemir plus insulin aspart versus NPH plus insulin aspart regimens
    Valentine, WJ
    Wittrup-Jensen, KU
    Häuser, C
    Roze, S
    [J]. DIABETOLOGIA, 2005, 48 : A334 - A334
  • [26] Cost-effectiveness analysis of basal-bolus therapy of type 1 diabetes using insulin detemir plus insulin aspart versus NPH plus insulin aspart regimens
    Valentine, WJ
    Wittrup-Jensen, KU
    Palmer, AJ
    Roze, S
    [J]. DIABETES, 2005, 54 : A609 - A609
  • [27] Cost-effectiveness of insulin detemir versus insulin glargine for Thai type 2 diabetes from a payer's perspective
    Permsuwan, Unchalee
    Thavorn, Kednapa
    Dilokthornsakul, Piyameth
    Saokaew, Surasak
    Chaiyakunapruk, Nathorn
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (09) : 991 - 999
  • [28] Evaluation of exenatide vs. insulin glargine in type 2 diabetes: cost-effectiveness analysis in the German setting
    Mittendorf, T.
    Smith-Palmer, J.
    Timlin, L.
    Happich, M.
    Goodall, G.
    [J]. DIABETES OBESITY & METABOLISM, 2009, 11 (11): : 1068 - 1079
  • [29] COST-EFFECTIVENESS OF SWITCHING PATIENTS WITH TYPE 2 DIABETES FROM INSULIN GLARGINE TO INSULIN DETEMIR IN A CHINESE SETTING: A HEALTH ECONOMIC MODEL BASED ON THE PREDICTIVE STUDY
    Yang, L.
    Christensen, T.
    White, J.
    Sun, F.
    [J]. VALUE IN HEALTH, 2010, 13 (03) : A5 - A5
  • [30] Cost-Effectiveness of Switching Patients with Type 2 Diabetes from Insulin Glargine to Insulin Detemir in Chinese Setting: A Health Economic Model Based on the PREDICTIVE Study
    Yang, Li
    Christensen, Torsten
    Sun, Fengyu
    Chang, Jinghua
    [J]. VALUE IN HEALTH, 2012, 15 (01) : S56 - S59
12345